Taro Pharmaceutical Industries Ltd..
TARO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company dedicated to meeting the needs of patients through the discovery, development, manufacturing and marketing of the highest quality healthcare products. The company focuses primarily on generic and proprietary...Show More
Better Health for All
0
Taro Pharmaceuticals' core business as a pharmaceutical company is dedicated to meeting patient needs through healthcare products, including a product like Keveyis which addresses an unmet need for an ultra-rare disease.
1
The company had two voluntary recalls in the past three years: one in January 2020 for Lamotrigine tablets due to cross-contamination, and another in December 2021 for Clobetasol Propionate Ointment due to bacterial contamination.
2
,
3
No adverse events or complaints were reported for either recall.
4
,
5
The company demonstrates good risk transparency by issuing press releases and notifying distributors and customers via multiple channels for both recalls, and by making full prescribing information for Keveyis available on its website.
6
,
7
,
8
Fair Money & Economic Opportunity
0
Taro Pharmaceutical Industries Ltd. is a pharmaceutical company, not a financial institution. The 'Fair Money & Economic Opportunity' value assesses companies based on their financial services, such as lending, insurance, or money management. Taro does not offer consumer lending, deposit services, or other financial products. Consequently, KPIs like underserved client share, pricing fairness (APRs/fees), exploitative fee exposure, inclusion initiatives (loan/insurance book), data accessibility (customer finance data), wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion (financial access points), and product simplicity (financial products) are not applicable to its core business model. While Taro has faced significant fines and settlements, including $213.2 million for False Claims Act charges
1
, a $205.6 million criminal penalty for collusive conduct
2
, a $75 million settlement for antitrust litigation
3
, and $200 million to resolve price-fixing allegations
4
, these regulatory actions pertain to pharmaceutical market practices and drug pricing, not fair lending compliance. Evidence of R&D investment by its parent company, Sun Pharma
5
, or Taro's retention of earnings for business development
6
, does not constitute reinvestment in community finance or profit-sharing with underserved communities as defined by the rubric.
Fair Pay & Worker Respect
-20
The company's employee rating is 2.8 out of 5 stars, based on 171 reviews
1
, which translates to an engagement score of 56 out of 100.
2
No specific, quantitative data was available for living wage coverage, CEO median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
3
Fair Trade & Ethical Sourcing
0
The provided article is a Code of Conduct for suppliers and service providers, outlining expectations regarding labor practices, environmental considerations, and business ethics, including human rights, child labor, forced labor, and responsible sourcing of minerals
1
. However, the document explicitly states that it contains no quantitative data, regulatory actions, violations, fines, certifications, awards, or comparisons to industry benchmarks
2
. Therefore, there is no specific, concrete evidence to score any of the KPIs against the rubric's quantitative thresholds.
Honest & Fair Business
0
Taro Pharmaceutical Industries Ltd. entered into a five-year corporate integrity agreement (CIA) requiring internal monitoring, price transparency, risk assessment, executive recoupment, and compliance certifications.
1
This agreement followed criminal antitrust cases and False Claims Act charges related to price-fixing, supply, and allocation of customers for generic drugs between 2013 and 2015.
2
The company incurred $419 million in penalties for these actions, comprising $205.7 million in criminal penalties and $213.3 million in civil penalties.
3
Kind to Animals
-40
Taro Pharmaceutical Industries Ltd. conducts pre-clinical trials on animals.
1
Its parent company, Sun Pharma, has a policy, revised in 2025, that commits to the 'Three Rs' principle (Replace, Reduce, Refine) for animal testing.
2
The policy states that animal testing should comply with applicable laws and regulations, and special care must be taken for animal welfare, particularly for higher-order species.
3
Sun Pharma's Supplier Code of Conduct also requires suppliers to treat animals ethically and compassionately, and to employ alternatives where scientifically valid and regulatory acceptable.
4
No War, No Weapons
0
The provided articles explicitly state that no specific data related to the 'No War, No Weapons' ethical value, including metrics on arms contracts, dual-use technology, sales to embargoed regimes, or peacebuilding investments, was found or is available for Taro Pharmaceutical Industries Ltd.
1
Therefore, no KPIs can be scored based on the evidence.
Planet-Friendly Business
0
The provided article focuses on Taro Pharmaceutical Industries Ltd.'s overall ESG Risk Rating of 34.9 (High)
1
and its industry rank of 579 out of 847 in the Pharmaceuticals industry
2
. It notes the company's management is 'Weak'
3
and exposure is 'Medium Low'
4
. However, the article explicitly states that no quantitative data on any specific environmental metrics, regulatory actions, violations, fines, or compliance issues are provided, making it impossible to assess performance against the detailed Planet-Friendly Business KPIs.
Respect for Cultures & Communities
0
No relevant information regarding Taro Pharmaceutical Industries Ltd.'s respect for cultures and communities could be extracted from the provided article. The article was a job posting for a different company, Sun Pharma
1
, and contained no data applicable to TARO.US.
2
Safe & Smart Tech
-40
In March 2023, Taro Pharmaceuticals U.S.A., Inc. experienced a data security incident
1
where unauthorized access occurred on March 3, 2023.
2
This incident affected over 1,700 current and former employees
3
, with exposed sensitive data including names, Social Security numbers, Driver's license numbers, and Passport numbers.
4
The breach was discovered on March 25, 2023
5
, and affected individuals were notified on April 19, 2023.
6
A class action lawsuit was filed alleging negligence in security safeguards and inadequate employee cybersecurity training
7
, which has since led to a proposed settlement.
8
Zero Waste & Sustainable Products
0
No quantitative data specific to Taro Pharmaceutical Industries Ltd. (TARO.US) regarding waste diversion, product recyclability, packaging sustainability, recycled content, or other zero-waste metrics was found in the provided articles. Articles
1
,
2
, and
3
explicitly refer to 'Sun Pharmaceutical Industries Limited' and state they do not contain data relevant to TARO.US.
4
,
5
,
6
, while about Taro Pharmaceutical Industries Ltd., explicitly states that no quantitative data related to waste or sustainable products is provided, focusing instead on overall ESG risk ratings.
7